Germany Spends 2.5 Billion Euros on 100 Million Bivalent Boosters Only to Discover That Nobody Wants Them

A strange fate for such safe and effective products. Big think emoji.

By eugyppius
Global Research, October 03, 2022
eugyppius 2 October 2022
Region:
Theme:

All Global Research articles can be read in 51 languages by activating the Translate This Article button below the author’s name.

To receive Global Research’s Daily Newsletter (selected articles), click here.

Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

***

The German government has ordered 100 million doses of BA.1 and BA.4/5 bivalent vaccines at a cost of 2.5 billion Euros, and almost nobody wants them. An amusing Welt article chronicles the scenes unfolding at our deserted regional vaccination centres, which for some reason are still open:

Michael Hubmann did not expect that so few would come. Only 85 people had themselves vaccinated against Covid-19 on Thursday in Fürth in Middle Franconia, a district with 120,000 inhabitants. “We’ve tried to make it as easy as possible for people,” says Hubmann, a paediatrician who is coordinating the vaccination campaign. He explains that vaccinations were offered simultaneously in two shopping centres, a bus, a home for the elderly and in a former shop in the pedestrian zone. “Yet hardly anyone wanted to have the fourth dose.”

The medical bureaucrats are baffled, just baffled:

“Unfortunately, interest in the fourth dose has been pretty low so far,” says Markus Beier, Chairman of the German Association of General Practitioners. At the same time, he says it’s important that people over 60 and those with previous illnesses in particular protect themselves with a further dose. “There is uncertainty among the population as to what further vaccinations will achieve. But they still strengthen protection against severe outcome.”

Meanwhile, vast quantities of vaccine are expiring. At the end of August alone, 3.9 million doses of Moderna and another 700,000 doses of Novavax had to be binned.

Bivalent booster uptake fail. (Source: eugyppius)

The chart above tells the whole sordid story of our recent experiment with mass vaccination. Demand for this snake oil was highest in the beginning, before anybody had any direct experience with it; and in the Fall, when the government tied vaccination to specific social privileges. As overt vaccinator coercion has faded and millions of people have tried these doubtful elixirs for themselves, interest has all but entirely evaporated. This is the ultimate vindication for all those who have been saying that the vaccines are lousy overhyped pharmaceuticals with a bad side-effect profile. A safe and effective product would only gain momentum with the population. It took less than two years for these to wear out their welcome.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Featured image is from Mercola
Articles by: eugyppius

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]